New Jersey Prescription Opioid Drug Abuse Seminar

AGENDA

WILLIAM PATERNSON UNIVERSITY
WAYNE, NEW JERSEY
SEPTEMBER 25, 2019

8:00am
Video: Impact of Opioid Abuse

Opening Remarks
Susan A. Gibson, Special Agent in Charge, Drug Enforcement Administration, New Jersey Division

Keynote Address: The Opioid Epidemic
Gurbir S. Grewal, New Jersey Attorney General

DEA Diversion Control Mission and Overview
Nancy Coffey, DEA Diversion Program Manager

9:00am - 9:30am
Drugs of Abuse and Current Trends
Luis Carrion, DEA Diversion Group Supervisor, Camden Resident Office

9:30am - 10:00am
Methods of Diversion and Effective Controls for Controlled Substances / Red Flags
Luis Carrion, DEA Diversion Group Supervisor, Camden Resident Office

10:00am - 10:15am
BREAK

10:15am - 10:45am
New Jersey State Board of Medical Examiners / Current Issues
Paul R. Rodriguez, Acting Director, New Jersey Division of Consumer Affairs

10:45am - 12:00pm
Distinguishing Drug-Seeking from Pain Relief-Seeking
Daniel P. Alford, MD, MPH, Director, Clinical Addiction Research and Education (CARE) Unit
Boston University School of Medicine | Boston Medical Center

12:00pm - 1:00pm
LUNCH
New Jersey Prescription Opioid Drug Abuse Seminar

AGENDA
WAYNE, NEW JERSEY
SEPTEMBER 25, 2019

1:00pm - 1:30pm
Health Care Fraud and Diversion
*John Croes*, Assistant Special Agent in Charge, US OIG-HHS, New York Regional Office

1:30pm - 2:45pm
Pain Management and Appropriate Opioid Prescribing Practices
*Thomas A. Viola*, R.Ph., C.C.P.

2:45pm - 3:15pm
New Jersey Prescription Drug Monitoring Program (PDMP)
*Paul R. Rodriguez*, Acting Director, New Jersey Division of Consumer Affairs

3:15pm - 3:30pm
BREAK

3:30pm - 4:00pm
Disposal Issues: Return of Patient Meds / Options for Patients / Take Back
*Luis Carrion*, DEA Diversion Group Supervisor, Camden Resident Office

4:00pm - 4:30pm
Legal Perspective on the Opioid Epidemic
*Theresa M. DiGuglielmo*, Esq., Frier & Levitt, LLC

4:30pm - 5:00pm
Q&A
Panel Discussion
Closing Remarks

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Federation of State Medical Boards and the United States Drug Enforcement Administration. The Federation of State Medical Boards is accredited by the ACCME to provide continuing medical education for physicians. The Federation of State Medical Boards designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*The New Jersey Prescription Opioid Drug Abuse Seminar* is not funded by any commercial entity. DEA’s participation in this event as a co-sponsor does not constitute an endorsement by the DEA of FSMB or their products or services.